On May 22, 2026, Polpharma Biologics announced that it had entered into an exclusive licensing agreement with Tuteur to commercialize a biosimilar targeting autoimmune diseases across Latin America, excluding Brazil. The parties did not disclose which specific biosimilar is covered by the license. Under the agreement, Polpharma Biologics will retain…
